MEDICINOVA INC (MNOV) Form 10-Q — May 14, 2026
MediciNova reported a net loss of $2.6 million for the quarter ended March 31, 2026, driven by $1.3 million in R&D expenses and $1.6 million in general and administrative costs. The company recognized $0.2 million in revenue from its clinical research services agreement with Mayo Foundation for Medical Education and Research. Cash and cash equivalents stood at $27.3 million at quarter-end, down from $30.8 million at the end of 2025. Management stated it has sufficient working capital to fund operations through at least May 2027.
Key figures
- Revenue
- 186984
- Total Debt
- 0
- Total Assets
- 42704854
- Cash Position
- 27329415
- Shares Outstanding
- 49221246
- Ga Expense
- 1590175
- Rd Expense
- 1262514
- Sepa Capacity
- 30000000
- Interest Income
- 252964
- Stock Based Compensation
- 407761
- Equity Distribution Capacity
- 50000000
Price after filing
Close on the filing date to close N calendar days later (from $1.40). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.